1. Introduction {#sec1-ijms-19-01487}
===============

Medical mushrooms have been approved as cures in traditional East Asian therapies \[[@B1-ijms-19-01487],[@B2-ijms-19-01487]\]. Scientists around the world have verified the unique properties of compounds extracted from mushrooms in the prevention and treatment of cancer and other chronic diseases \[[@B3-ijms-19-01487]\].

*Sparassis crispa* (*S. crispa*) is a species of fungus belonging to the genus Sparassis, known as Cauliflower mushroom or *Sparassis latifolia*; also called by other names such as Hanabiratake in Japanese \[[@B2-ijms-19-01487],[@B3-ijms-19-01487],[@B4-ijms-19-01487]\]. *S. crispa* is not only an edible mushroom but also a well-known medicinal mushroom that has many medical applications \[[@B3-ijms-19-01487],[@B5-ijms-19-01487]\] (e.g., anti-tumor and anti-carcinogenic properties; anti-inflammatory, antiviral, anti-hypertensive, anti-allergic, anti-diabetic activities, and cytokine induction \[[@B1-ijms-19-01487],[@B2-ijms-19-01487],[@B3-ijms-19-01487],[@B6-ijms-19-01487],[@B7-ijms-19-01487]\]). Recently, this mushroom has been widely utilized in Japan and Korea \[[@B3-ijms-19-01487],[@B7-ijms-19-01487],[@B8-ijms-19-01487]\].

*S. crispa* contains highly active biological and pharmacological ingredients (e.g., β-glucan, anti-fungal compounds (sparassol, methyl-2,4-dihydroxy-6-methylbenzoate, and methyl-dihydroxymethoxy-methylbenzoate), ergosterol peroxides, and benzoate derivatives) that are useful in the treatment of human disease \[[@B3-ijms-19-01487],[@B5-ijms-19-01487],[@B9-ijms-19-01487],[@B10-ijms-19-01487],[@B11-ijms-19-01487]\]. In particular, β-glucan can prevent and heal common health problems such as diabetes, cancer, wound healing, as well as immune system and cytokine induction \[[@B1-ijms-19-01487],[@B6-ijms-19-01487],[@B12-ijms-19-01487],[@B13-ijms-19-01487],[@B14-ijms-19-01487],[@B15-ijms-19-01487]\]. In addition, phenolic compounds, anti-fungal substances, and other *S. crispa* extracts may be used as anti-oxidant or anti-fungal agents \[[@B3-ijms-19-01487],[@B16-ijms-19-01487],[@B17-ijms-19-01487],[@B18-ijms-19-01487],[@B19-ijms-19-01487]\].

Several studies have indicated, through tests on either mice or human cell lines, that *S. crispa* is a potential natural source of medicinal ingredients that can contribute to the limitations and even prevention of human disease (e.g., cancer, allergies, and especially diabetic disease) \[[@B12-ijms-19-01487],[@B13-ijms-19-01487],[@B19-ijms-19-01487],[@B20-ijms-19-01487]\] However, in individual studies, scientists have not focused on the overall assessments of the benefits of *S. crispa* in human health as a systematic review. Thus, this study reviewed randomized and controlled trials, also conducted a systematic review and meta-analysis to evaluate the statistically significant benefits of *S. crispa* in therapeutic approaches.

2. Results {#sec2-ijms-19-01487}
==========

2.1. Characteristics of Included Studies {#sec2dot1-ijms-19-01487}
----------------------------------------

[Figure 1](#ijms-19-01487-f001){ref-type="fig"} shows the flow of candidate and eligible articles. Our searches in databases yielded a total of 623 different publications whose titles and abstracts were screened and 270 were considered relevant only by title and abstract. After reviewing these 270 full-text articles on the efficiency of *S. crispa* extracts for human-disease treatment, thirty-three articles were considered eligible and, therefore, included in the quantitative meta-analysis. One of those articles was written in Japanese \[[@B21-ijms-19-01487]\], seven in Korean \[[@B19-ijms-19-01487],[@B22-ijms-19-01487],[@B23-ijms-19-01487],[@B24-ijms-19-01487],[@B25-ijms-19-01487],[@B26-ijms-19-01487],[@B27-ijms-19-01487]\], and the remaining in English. Among them, some studies demonstrated more than two healing effects of the mushroom \[[@B7-ijms-19-01487],[@B26-ijms-19-01487],[@B28-ijms-19-01487],[@B29-ijms-19-01487],[@B30-ijms-19-01487]\]. Simultaneously, the anti-diabetic, anti-tumor, anti-inflammatory, anti-fungal, and antioxidant activities of *S. crispa* were reported in seven \[[@B6-ijms-19-01487],[@B12-ijms-19-01487],[@B14-ijms-19-01487],[@B28-ijms-19-01487],[@B29-ijms-19-01487],[@B30-ijms-19-01487],[@B31-ijms-19-01487]\], nine-teen \[[@B7-ijms-19-01487],[@B13-ijms-19-01487],[@B15-ijms-19-01487],[@B21-ijms-19-01487],[@B23-ijms-19-01487],[@B24-ijms-19-01487],[@B26-ijms-19-01487],[@B28-ijms-19-01487],[@B30-ijms-19-01487],[@B32-ijms-19-01487],[@B33-ijms-19-01487],[@B34-ijms-19-01487],[@B35-ijms-19-01487],[@B36-ijms-19-01487],[@B37-ijms-19-01487],[@B38-ijms-19-01487],[@B39-ijms-19-01487],[@B40-ijms-19-01487],[@B41-ijms-19-01487]\], four \[[@B7-ijms-19-01487],[@B22-ijms-19-01487],[@B30-ijms-19-01487],[@B42-ijms-19-01487]\], three \[[@B19-ijms-19-01487],[@B29-ijms-19-01487],[@B43-ijms-19-01487]\], and six \[[@B8-ijms-19-01487],[@B25-ijms-19-01487],[@B26-ijms-19-01487],[@B27-ijms-19-01487],[@B44-ijms-19-01487],[@B45-ijms-19-01487]\] studies, respectively.

All these thirty-three studies estimated the *S. crispa* benefits based on rats, diabetic mice, and cancer cell test (see [Table 1](#ijms-19-01487-t001){ref-type="table"}), and provided raw data for a standardized mean difference (SMD) estimation.

2.2. Risk of Bias {#sec2dot2-ijms-19-01487}
-----------------

To explore the validity of eligible randomized studies, the quality of bias assessment of the included studies was determined by evaluating the bias of the random sequence generation, allocation concealment, selective reporting, blinding of participants and outcome assessment, and incomplete outcome data based on three levels following the Cochrane guideline (low and high risk of bias that may indicate either lack of information or uncertainty over the potential for bias) \[[@B46-ijms-19-01487]\]. According to [Table 2](#ijms-19-01487-t002){ref-type="table"} and [Figure 2](#ijms-19-01487-f002){ref-type="fig"}, almost all criteria showed a low risk of bias, especially in studies where homogeneity in the random sequence generation criteria was used. Resulting in an evident enhanced of the statistical significance of the meta-analysis.

2.3. Diabetes Treatment {#sec2dot3-ijms-19-01487}
-----------------------

Anti-diabetic activity was evaluated by seven studies \[[@B6-ijms-19-01487],[@B12-ijms-19-01487],[@B14-ijms-19-01487],[@B28-ijms-19-01487],[@B29-ijms-19-01487],[@B30-ijms-19-01487],[@B31-ijms-19-01487]\] ([Figure 3](#ijms-19-01487-f003){ref-type="fig"} and [Table 3](#ijms-19-01487-t003){ref-type="table"}). Most of the assays were performed in diabetic rat and mouse cells, and the treatment was assessed in five aspects: serum glucose levels (mg/dL), serum insulin levels (mg/dL), nutrition intake (mL), body weight (g) of mice or tissues before and after treatment, as well as wound healing ability (%). In addition, some individual studies have identified and demonstrated the beneficial effects of *S. crispa* in several healing aspects, so they were evaluated in various separate analyses. For instance, Yamamoto et al. showed that *S. crispa* could prevent human diabetes by reducing serum glucose levels, insulin levels, and increasing the body weight of diabetic mice \[[@B14-ijms-19-01487]\]. In addition, Jeong et al. indicated the capability of *S. crispa* in four aspects including serum glucose and insulin levels, nutrition intake, and body weight \[[@B29-ijms-19-01487]\].

A subgroup analysis was conducted to quantify the effect of *S. crispa* in all therapeutic approaches comparing to the control group. Anti-diabetic activity was significantly higher in the *S. crispa* group than in the control group, and results showed a significant effect of *S. crispa* in the treatment (SMD = 1.29, 95% confidence interval (CI) (0.47, 2.11), *p* \< 0.00001), although a heterogeneity was observed in the subgroup analysis (heterogeneity X^2^ = 50.24, *p* \< 0.00001, I^2^ = 91.9%). However, when was considered each aspect of the diabetes treatment, the comparison between serum insulin levels and wound healing rates showed significant homogeneities in all reported symptoms and presented a large SMD between the two groups ((SMD = 1.92, 95% CI (1.10, 2.75), I^2^ = 0%) and (SMD = 3.55, 95% CI (2.56, 4.54), I^2^ = 40%), respectively). Neither nutrition intakes showed heterogeneity SMD (SMD = 0.32, 95% CI (−0.15, 0.78), I^2^ = 0%). Nevertheless, serum glucose levels and body weights of rats showed high heterogeneity (I^2^ = 94% and I^2^ = 78%, respectively).

2.4. Cancer Treatment {#sec2dot4-ijms-19-01487}
---------------------

From nine-teen studies \[[@B7-ijms-19-01487],[@B13-ijms-19-01487],[@B15-ijms-19-01487],[@B21-ijms-19-01487],[@B23-ijms-19-01487],[@B24-ijms-19-01487],[@B26-ijms-19-01487],[@B28-ijms-19-01487],[@B30-ijms-19-01487],[@B32-ijms-19-01487],[@B33-ijms-19-01487],[@B34-ijms-19-01487],[@B35-ijms-19-01487],[@B36-ijms-19-01487],[@B37-ijms-19-01487],[@B38-ijms-19-01487],[@B39-ijms-19-01487],[@B40-ijms-19-01487],[@B41-ijms-19-01487]\], seven reported an anti-tumor activity, five showed an inhibition of cancer cell viability, and nine indicated IFN-$\gamma$ induction of *S. crispa* extracts. On the other hand, there are several reports which showed appropriate data in many respects \[[@B3-ijms-19-01487],[@B7-ijms-19-01487]\]. In addition, when considering the capability of healing, researchers performed experiments to describe the effect of *S. crispa* extract in various types of cells \[[@B3-ijms-19-01487],[@B15-ijms-19-01487],[@B23-ijms-19-01487]\] or to determine the therapeutic potential of different *S. crispa* extracts on a cell type \[[@B7-ijms-19-01487]\]. Therefore, these studies have been evaluated and appeared multiple times in a comparison of this analysis. An individual analysis was applied to two groups for each of those aspects, showing significant inter-group differences (see [Figure 4](#ijms-19-01487-f004){ref-type="fig"}, [Figure 5](#ijms-19-01487-f005){ref-type="fig"} and [Figure 6](#ijms-19-01487-f006){ref-type="fig"}).

A comparison between the control and *S. crispa* group showed a lower tumor cell activity (SMD = 2.22, 95% CI (1.69, 2.75), *p* \< 0.00001); that reduction was relevant to the homogeneity in seven studie \[[@B7-ijms-19-01487],[@B13-ijms-19-01487],[@B15-ijms-19-01487],[@B24-ijms-19-01487],[@B30-ijms-19-01487],[@B34-ijms-19-01487],[@B35-ijms-19-01487]\] (X^2^ = 24.27, I^2^ = 42%). Additionally, the heterogeneity was not significant for the survival of cancer cells (X^2^ = 12.11, I^2^ = 34%) in five studies \[[@B7-ijms-19-01487],[@B23-ijms-19-01487],[@B30-ijms-19-01487],[@B33-ijms-19-01487],[@B36-ijms-19-01487]\], resulting in a dramatical decrease in the cancer cell viability after exposure to *S. crispa* (SMD = 21.36, 95% CI (17.91, 24.81), *p* \< 0.00001). The SMD between these two groups did not show a significant of the IFN-$\gamma$ induction aspect (SMD = −0.34, 95% CI (−0.37, −0.31), X^2^ = 1168.88, I^2^ = 99%).

2.5. Anti-Inflammatory Activity {#sec2dot5-ijms-19-01487}
-------------------------------

Data about anti-inflammatory activities of *S. crispa* extracts were reported in four studies \[[@B7-ijms-19-01487],[@B22-ijms-19-01487],[@B30-ijms-19-01487],[@B42-ijms-19-01487]\]. According to SMDs ([Figure 7](#ijms-19-01487-f007){ref-type="fig"} and [Figure 8](#ijms-19-01487-f008){ref-type="fig"}, and [Table 3](#ijms-19-01487-t003){ref-type="table"}), those results demonstrated that *S. crispa* reduced inflammatory cells survival (SMD = 9.03, 95% CI (0.80, 17.27), X^2^ = 3.74, I^2^ = 47%). The heterogeneity did not exist when was compared the NO production potential between control and *S. crispa* groups, with a large effect (SMD = 4.81, 95% CI (3.30, 6.33), X^2^ = 4.01, I^2^ = 50%).

2.6. Anti-Fungal Activity {#sec2dot6-ijms-19-01487}
-------------------------

Anti-fungal compounds are produced by *S. crispa* in cultures and in wood decomposed naturally, as reported in three studies \[[@B19-ijms-19-01487],[@B29-ijms-19-01487],[@B43-ijms-19-01487]\]. According to these studies, results of the meta-analysis ([Figure 9](#ijms-19-01487-f009){ref-type="fig"}) there was a favorable effect in the *S. crispa* group; the numbers of bacteria and fungi were reduced in the treatment group compared with the control group. A significant difference was found between these two groups (SMD = 0.20, 95% CI (−0.23, 0.62), X^2^ = 8.86, I^2^ = 44% \< 50%).

2.7. Antioxidant Activity {#sec2dot7-ijms-19-01487}
-------------------------

According to six studies \[[@B8-ijms-19-01487],[@B25-ijms-19-01487],[@B26-ijms-19-01487],[@B27-ijms-19-01487],[@B44-ijms-19-01487],[@B45-ijms-19-01487]\], the antioxidant activity was performed through DPPH (2, 2-diphenyl-1-picrylhydrazyl radical scavenging activity and the oxidative-inhibitory capacity of phenolic compounds derived from *S. crispa*. In both cases, the *S. crispa* group reported a higher level of oxidative protection than the control group, with evidence of improving antioxidant activity ([Figure 10](#ijms-19-01487-f010){ref-type="fig"} and [Figure 11](#ijms-19-01487-f011){ref-type="fig"}). The inhibitory activity indicated a significant homogeneity with I^2^ = 0% and X^2^ = 1.10 (SMD = −7.72, 95% CI (−10.96, −4.49), *p* \< 0.00001), while the DPPH activity showed a very high statistical significance in the inter-group comparison of four relevant studies (SMD = −26.50, 95% CI (−38.35, −14.64), *p* \< 0.00001, X^2^ = 3.32, I^2^ = 10%).

2.8. Sensitivity Analysis {#sec2dot8-ijms-19-01487}
-------------------------

Studies that used the same *S. crispa* extract, similar dosages and the same experimental objects were included in the sensitivity analysis. Wound healing rates in diabetes treatment and survival of cancer cells after anti-tumor activity were analyzed ([Figure 12](#ijms-19-01487-f012){ref-type="fig"} and [Figure 13](#ijms-19-01487-f013){ref-type="fig"}). All cases showed a high homogeneity and a high reduction of the percentages of cancer cells (SMD = 16.08 (1.83, 27.32), I^2^ = 0%), as well as an improved wound healing ability of the objects (SMD = 2.89 (1.87, 3.90), I^2^ = 13%) after treatment with *S. crispa*.

2.9. Bias Analysis {#sec2dot9-ijms-19-01487}
------------------

Funnel plots were drawn to assess the publication bias of studies on the medical applications of *S. crispa*. [Figure 14](#ijms-19-01487-f014){ref-type="fig"} and [Figure 15](#ijms-19-01487-f015){ref-type="fig"} are approximately symmetrical but small studies showing diabetes and cancer treatment effects of *S. crispa* remain unpublished. In contrast, [Figure 16](#ijms-19-01487-f016){ref-type="fig"} estimated that the most important studies on anti-inflammatory activity of *S. crispa* have been missing, so the outcomes of the anti-inflammatory treatment were not highly significant statistically. Even though the funnel plots in [Figure 17](#ijms-19-01487-f017){ref-type="fig"} and [Figure 18](#ijms-19-01487-f018){ref-type="fig"} also demonstrated that many relevant studies have not been published yet, all the published data were statistically significant for the anti-fungal and antioxidant activity of *S. crispa* extracts.

3. Discussion {#sec3-ijms-19-01487}
=============

In this systematic review and meta-analysis of thirty-three studies on the medical application of *S. crispa* extracts were confirmed that *S. crispa* is not only an edible mushroom but also a medicinal mushroom that has been increasingly cultivated because of its potential value in traditional medicine. Indeed, *S. crispa* contains highly physiological active substances (e.g., β-glucan, phenolic compounds, chloroform extract, and some antibiotic compounds) that can support a healthy level of blood-sugar and recovery of the normal cellular immunization \[[@B3-ijms-19-01487]\]. The beneficial effects have been demonstrated by anti-diabetic, anti-tumor, anti-inflammatory, anti-fungal, and anti-oxidant activities \[[@B1-ijms-19-01487],[@B3-ijms-19-01487],[@B11-ijms-19-01487],[@B20-ijms-19-01487],[@B47-ijms-19-01487]\]; almost all of the typical therapeutic effects of *S. crispa* showed significant differences, relative to the control groups.

As an immunomodulating substance, β-glucan plays an important role in most healing modalities \[[@B48-ijms-19-01487]\]. Mainly, involving an enhance of the immune response against cancer and stimulating the cells of the innate immune system \[[@B48-ijms-19-01487],[@B49-ijms-19-01487],[@B50-ijms-19-01487],[@B51-ijms-19-01487]\]. The discovery of specific receptors for glucans in cells, as well as interactions with other receptors mainly expressed by innate immune cells, have been reported as the primary mechanism of β-glucan for regulation of anti-tumor therapy and some associated medical treatments \[[@B51-ijms-19-01487]\]. Our meta-analysis indicated that *S. crispa* extracts had a large influence in reducing significantly cancer cells viability and tumor cells suppression ([Figure 4](#ijms-19-01487-f004){ref-type="fig"} and [Figure 5](#ijms-19-01487-f005){ref-type="fig"}). Although, here there was not a high homogeneity in the IFN-$\gamma$ production aspect ([Figure 6](#ijms-19-01487-f006){ref-type="fig"}). Moreover, the estimate as clinical evidence for a relationship between structure and activity, suggested the contributions of multiple receptor-ligand interactions in glycan-mediated immunopotentiation.

Diabetes that has been caused by a single high dose of streptozotocin is typically accompanied by symptoms such as weight loss, polyuria, hyperglycemia, and neuroendocrine dysfunction \[[@B6-ijms-19-01487],[@B14-ijms-19-01487]\]. On the other hand, whereas wound healing progresses at an optimal rate in healthy individuals, patients with diabetes usually exhibit delayed or impaired wound healing, which is a serious high-blood-glucose-related clinical problem \[[@B52-ijms-19-01487]\]. The present subgroup analysis did not report any significant difference (I^2^ = 91.9%) between *S. crispa* and control groups ([Figure 3](#ijms-19-01487-f003){ref-type="fig"} and [Table 3](#ijms-19-01487-t003){ref-type="table"}), suggesting that mushroom extracts have not had complete effects on all the diabetes symptoms. However, an individual analysis for each aspect, two topical therapy symptoms (incidence of wounds and serum insulin levels in the blood) were eliminated after treatment with *S. crispa*. In summary, *S. crispa* showed a slightly beneficial influence on diabetes therapeutics. Meanwhile, we expect that additional studies on *S. crispa* treatments will improve the accuracy of the analysis.

Additionally, the mushroom has shown an anti-inflammatory activity \[[@B1-ijms-19-01487],[@B2-ijms-19-01487],[@B47-ijms-19-01487]\]. The present analysis estimates ([Figure 7](#ijms-19-01487-f007){ref-type="fig"} and [Figure 8](#ijms-19-01487-f008){ref-type="fig"}, and [Table 3](#ijms-19-01487-t003){ref-type="table"}) that studies on anti-inflammatory therapy were statistically significant, achieving a small homogeneity in the analysis. Furthermore, results also demonstrated that *S. crispa* extracts played an inhibitory role in inflammatory responses via regulation of NO production; suggesting a potential role as a component of inflammatory drugs.

Recently, some evidence has suggested that the biological actions of phenolic compounds are associated with their antioxidant capacity based on their ability to chelate metals and lipoxygenase inhibitors \[[@B19-ijms-19-01487],[@B26-ijms-19-01487]\]. The present survey also considered and evaluated antioxidant activities of the medical mushroom by meta-analysis ([Figure 10](#ijms-19-01487-f010){ref-type="fig"} and [Figure 11](#ijms-19-01487-f011){ref-type="fig"}). According to the coefficient of heterogeneities of the analysis (I^2^ = 0% and 10%), it was confirmed that phenolic compounds and other *S. crispa* extracts could significantly contribute to antioxidant properties; explaining the relationship between phenolic compounds and antioxidant activities, as well as anti-fungal ability.

Finally, anti-bacterial and anti-fungal compounds have been identified in *S. crispa* \[[@B43-ijms-19-01487]\], though their utilities were reported in only three studies \[[@B19-ijms-19-01487],[@B29-ijms-19-01487],[@B43-ijms-19-01487]\]. The analysis showed that after exposure to *S. crispa* extracts the numbers of bacteria and fungi were reduced, indicating that the mushroom, as a component of pharmaceuticals, can protect humans from bacterial and fungal contamination.

4. Materials and Methods {#sec4-ijms-19-01487}
========================

4.1. Methods {#sec4dot1-ijms-19-01487}
------------

The study followed the Cochrane Collaboration method \[[@B46-ijms-19-01487]\], as well as the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@B53-ijms-19-01487]\] to report a systematic review and meta-analysis. Also, this work was based on the protocols and reviews on medical applications of *S. crispa*. It included all the researches that assessed the ability of *S. crispa* extracts on human health treatment (i.e., diabetes and cancer treatment, anti-fungal, antioxidant, and anti-inflammatory activity). It excluded ineligible studies such as studies of the effects of mushroom in other application fields and contained inappropriate data for the analysis. It compared and analyzed the statistical significance of individual studies of the same effect of *S. crispa* for the specific therapeutics using meta-analysis. Outcomes provided an overview and a systematic assessment about the clinical efficacies of *S. crispa* based on comparing SMDs between control and *S. crispa* groups, as well as the heterogeneity coefficient (I^2^) of each analysis \[[@B54-ijms-19-01487]\].

4.2. Literature Search and Data Extraction {#sec4dot2-ijms-19-01487}
------------------------------------------

### 4.2.1. Database Research Strategy {#sec4dot2dot1-ijms-19-01487}

The searched literature on medical applications of *S. crispa* extracts was performed in the databases PubMed (National Library of Medicine, Bethesda, MD, USA), EMBASE (Excerpta Medica database, Amsterdam, Netherlands), Elsevier (Information and Analytics, Amsterdam, Netherlands), CENTRAL (Cochrane Central Register of Controlled Trials, New York, NY, USA), and Web of Science (Institute of Scientific Information and Clarivate Analytics, Philadelphia, PA, USA), considering articles published between 1990 and 2018. Also, we made a hand searching for important conference papers, as well as checking reference lists. Combinations of the following keywords were used: *S. crispa*, *Sparassis Latifolia*, *Cauliflower mushroom*, *Hanaratake*, medical applications, immune stimulating activity, anti-tumor, anti-cancer, anti-microbial, anti-melanin, anti-metastatic, anti-inflammatory, anti-fungal, antioxidant, anti-viral, anti-diabetic, and anti-hypertensive activity. The respective reference lists of the identified papers also were searched. All articles were written in English, Korean or Japanese.

### 4.2.2. Data Extraction {#sec4dot2dot2-ijms-19-01487}

The bibliographic reference list was screened and manually selected from eligible studies from the electronic database for the meta-analysis, according to the criteria of associations between medical applications of *S. crispa* and human therapeutics. The following information from each article was obtained: article title, the name of first author, location, study year, publication year, study design, number of participants, dosage and administration, type of treatment and outcomes. These items were selected based on the presence and short descriptions of important study characteristics (e.g., title, abstract, study design, experimental object, and kind of medical application). The criteria included in the quantitative meta-analysis were empirical data that could be used to calculate the SMDs of treatments.

### 4.2.3. Exclusion Criteria {#sec4dot2dot3-ijms-19-01487}

Articles were excluded based on the following criteria: no data presentation (e.g., review articles and editorials), incomplete data, repeated and similar studies.

4.3. Meta-Analysis {#sec4dot3-ijms-19-01487}
------------------

For each analysis, we determined the effect size (SMD) and 95% CI for the comparison between control and *S. crispa* groups. The SMD was obtained by dividing the mean difference between the two groups by the pooled variance, with adjustment for small samples. We considered SMDs about 0.2 or less as small values, 0.5 as moderate values, and 0.8 or greater values as large \[[@B54-ijms-19-01487]\]. We quantified the extension to which the observed variability between studies was due to true differences between studies using the I^2^ statistic. Heterogeneity was considered to be small when I^2^ was less than 25%, moderate when 25--50%, and large when greater than 50% \[[@B54-ijms-19-01487]\]. The subgroup analysis assessed the overall effects in the subgroups according to the model type, kind(s) of treatment(s), and symptoms. The value of *p* \< 0.05 was considered statistically significant, and bias was examined using a funnel plot.

All these analyses were performed using Review Manager \[[@B46-ijms-19-01487]\] (version 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

5. Limitation of Study {#sec5-ijms-19-01487}
======================

The limitation of this study is the number of individual studies, which are not as large as our expectation in some respect (i.e., anti-inflammatory, anti-fungal, and antioxidant activity) leading to estimations not highly significant. Especially in the sensitivity assessment, the results might be not high accuracy because of a very small quantity of those that have the same test conditions for consideration of the sensitivity.

6. Conclusions {#sec6-ijms-19-01487}
==============

Briefly, this investigation determined that *S. crispa* is useful in medical therapeutics, each extract showed their properties and specific applications. Particularly, a meta-analysis revealed that β-glucan, which is known as the primary ingredient of *S. crispa* extract, plays an important part in the treatment of cancer and diabetes. Additionally, the analysis confirmed that β-glucan and other constituents (i.e., phthalide compounds, low-molecular-weight ingredients, and anti-bacterial substances) are used in anti-inflammatory activities, as well as antioxidant and anti-fungal immunotherapies. However, recent studies have focused on the clinical application of *S. crispa* \[[@B3-ijms-19-01487],[@B12-ijms-19-01487],[@B13-ijms-19-01487],[@B26-ijms-19-01487],[@B31-ijms-19-01487],[@B35-ijms-19-01487],[@B44-ijms-19-01487]\]. To support our analysis, further studies to improve the statistical significance is necessary.
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###### 

Summary of the characteristics of the studies included in this work.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                         Characteristic of Object       *S. crispa* Extract Compound   Medical Therapeutic   *n*      Dosage                          Location
  ------------------------------------------------- ------------------------------ ------------------------------ --------------------- -------- ------------------------------- ----------------
  \[[@B6-ijms-19-01487]\] Kwon et al., 2009         Mice                           β-glucan                       Anti-diabetic         10       100 µg/mL β-glucan              Korea

  \[[@B32-ijms-19-01487]\] Kim et al., 2010         Dendritic cell                 β-glucan                       Anti-tumor            3        100 µg/mL β-glucan              Korea

  \[[@B31-ijms-19-01487]\] Yoshitomi et al., 2011   Mice                           β-glucan                       Anti-diabetic         8        100 µg/mL β-glucan              Japan

  \[[@B33-ijms-19-01487]\] Lee et al., 2010         RAW 264.7 cell                 β-glucan                       Anti-tumor            3        250 µg/mL β-glucan              Korea

  \[[@B34-ijms-19-01487]\] Choi et al., 2016        Human fibrinogen               Wulfase                        Anti-tumor            3        200 µg/mL Wulfase               Korea

  \[[@B15-ijms-19-01487]\] Harada et al., 2002a     CD 41 and CD 81 cell           β-glucan                       Anti-tumor            3        200--250 µg/mL β-glucan         Japan

  \[[@B35-ijms-19-01487]\] Harada et al., 2003      Mice                           β-glucan                       Anti-tumor            4        25 µg/mL β-glucan               Japan

  \[[@B28-ijms-19-01487]\] Yamamoto et al., 2009    C57BL/6J cell/Mice cell line   β-glucan                       Anti-diabetic\        10       160 µg/mL β-glucan              Japan
                                                                                                                  Anti-tumor                                                     

  \[[@B7-ijms-19-01487]\] Yoshikama et al., 2010    RAW 264.7 cell                 Phthalide compounds            Anti-tumor            3--4     100 µg/mL phthalide compound    Japan

  \[[@B21-ijms-19-01487]\] Yamamoto et al., 2007    Sarcoma180 cell                *S. crispa* extract            Anti-tumor            3        35 µg/mL β-glucan               Japan

  \[[@B14-ijms-19-01487]\] Yamamoto et al., 2010    Mice                           *S. crispa* extract            Anti-diabetic         6--8     100 µg/mL β-glucan              Japan

  \[[@B29-ijms-19-01487]\] Jeong et al., 2017       Mice                           β-glucan                       Anti-diabetic\        12       100 µg/mL β-glucan              Korea
                                                                                                                  Anti-fungal                                                    

  \[[@B22-ijms-19-01487]\] Choi et al., 2013        RAW 264.7 cell                 β-glucan                       Anti-inflammatory     3        200 µg/mL β-glucan              Korea

  \[[@B23-ijms-19-01487]\] Choi et al., 2014        A529 cell\                     β-glucan                       Anti-tumor            12       250 µg/mL β-glucan              Korea
                                                    HepG2 cell\                                                                                                                  
                                                    AGS cell                                                                                                                     

  \[[@B30-ijms-19-01487]\] Kimura T. 2013           Sarcoma 180 cell\              β-glucan                       Anti-diabetic\        3--5     100 µg/mL β-glucan              Japan
                                                    Mice\                                                         Anti-tumor\                                                    
                                                    Colon cancer cell\                                            Anti-inflammatory                                              
                                                    F3444N/Rat                                                                                                                   

  \[[@B42-ijms-19-01487]\] Kim et al., 2012         Mast cell (HMC-1)              *S. crispa* extract            Anti-inflammatory     3        200 µg/mL *S. crispa* extract   Korea

  \[[@B36-ijms-19-01487]\] Hu et al., 2016          PC12 cell                      β-glucan                       Anti-tumor            6        250 µg/mL β-glucan              China

  \[[@B44-ijms-19-01487]\] Puttaraju et al., 2006   Mice                           *S. crispa* extract            Antioxidant           3        30 µg/mL β-glucan               India

  \[[@B8-ijms-19-01487]\] Kim et al., 2008          Mice or cell                   *S. crispa* extract            Antioxidant           3        100 µg/mL *S. crispa* extract   Korea

  \[[@B43-ijms-19-01487]\] Woodward et al., 1992    Botrytis cinerea               Antibiotic compounds           Anti-fungal           10       100 µg/mL antibiotic compound   United Kingdom

  \[[@B13-ijms-19-01487]\] Ohno et al., 2000        Mice                           *S. crispa* extract            Anti-tumor            10       250 µg/mL *S. crispa* extract   Japan

  \[[@B12-ijms-19-01487]\] Yamamoto et al., 2014    Mice                           β-glucan                       Anti-diabetic         10--18   250 µg/mL β-glucan              Japan

  \[[@B19-ijms-19-01487]\] Lee et al., 2013a        Soybean                        *S. crispa* extract            Anti-fungal           3        125 µg/mL *S. crispa* extract   Korea

  \[[@B24-ijms-19-01487]\] Kim et al., 2013         Raw 264.7 cell                 β-glucan                       Anti-tumor            5        100 µg/mL β-glucan              Korea

  \[[@B37-ijms-19-01487]\] Harada et al., 2002b     Mice                           β-glucan                       Anti-tumor            5        100 µg/mL β-glucan              Japan

  \[[@B38-ijms-19-01487]\] Harada et al., 2004      Mice                           β-glucan                       Anti-tumor            3        100 µg/mL β-glucan              Japan

  \[[@B39-ijms-19-01487]\] Harada et al., 2006      Mice                           β-glucan                       Anti-tumor            3        100 µg/mL β-glucan              Japan

  \[[@B40-ijms-19-01487]\] Nameda et al., 2003      Mice                           β-glucan                       Anti-tumor            3        50 µg/mL β-glucan               Japan

  \[[@B41-ijms-19-01487]\] Yao et al., 2008         Mice                           β-glucan                       Anti-tumor            10       120 µg/mL β-glucan              China

  \[[@B25-ijms-19-01487]\] Lee et al., 2016a        Soybean                        β-glucan                       Antioxidant           3        200µg/mL β-glucan               Korea

  \[[@B26-ijms-19-01487]\] Park et al., 2016        Mice                           *S. crispa* extract            Antioxidant           6        200 µg/mL *S. crispa* extract   Korea

  \[[@B27-ijms-19-01487]\] Lee et al., 2016b        Cell                           *S. crispa* extract            Antioxidant           3        50 µg/mL β-glucan               Korea

  \[[@B45-ijms-19-01487]\] Lee et al., 2013b        Mice                           Phenolic compounds             Antioxidant           3        200 µg/mL phenolic compounds    Korea
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Risk of bias rating of each study.

  Study                                             Random Sequence Generation   Allocation Concealment   Selective Reporting   Blinding of Participants   Blinding of Outcome Assessment   Incomplete Outcome Data
  ------------------------------------------------- ---------------------------- ------------------------ --------------------- -------------------------- -------------------------------- -------------------------
  \[[@B6-ijms-19-01487]\] Kwon et al., 2009                                                                                                                                                 
  \[[@B32-ijms-19-01487]\] Kim et al., 2010                                                                                                                                                 
  \[[@B31-ijms-19-01487]\] Yoshitomi et al., 2011                                                                                                                                           
  \[[@B33-ijms-19-01487]\] Lee et al., 2010                                                                                                                                                 
  \[[@B34-ijms-19-01487]\] Choi et al., 2016                                                                                                                                                
  \[[@B15-ijms-19-01487]\] Harada et al., 2002a                                                                                                                                             
  \[[@B35-ijms-19-01487]\] Harada et al., 2003                                                                                                                                              
  \[[@B28-ijms-19-01487]\] Yamamoto et al., 2009                                                                                                                                            
  \[[@B7-ijms-19-01487]\] Yoshikama et al., 2010                                                                                                                                            
  \[[@B21-ijms-19-01487]\] Yamamoto et al., 2007                                                                                                                                            
  \[[@B14-ijms-19-01487]\] Yamamoto et al., 2010                                                                                                                                            
  \[[@B29-ijms-19-01487]\] Jeong et al., 2017                                                                                                                                               
  \[[@B22-ijms-19-01487]\] Choi et al., 2013                                                                                                                                                
  \[[@B23-ijms-19-01487]\] Choi et al., 2014                                                                                                                                                
  \[[@B30-ijms-19-01487]\] Kimura T. 2013                                                                                                                                                   
  \[[@B42-ijms-19-01487]\] Kim et al., 2012                                                                                                                                                 
  \[[@B36-ijms-19-01487]\] Hu et al., 2016                                                                                                                                                  
  \[[@B44-ijms-19-01487]\] Puttaraju et al., 2006                                                                                                                                           
  \[[@B8-ijms-19-01487]\] Kim et al., 2008                                                                                                                                                  
  \[[@B43-ijms-19-01487]\] Woodward et al., 1992                                                                                                                                            
  \[[@B13-ijms-19-01487]\] Ohno et al., 2000                                                                                                                                                
  \[[@B12-ijms-19-01487]\] Yamamoto et al., 2014                                                                                                                                            
  \[[@B19-ijms-19-01487]\] Lee et al., 2013a                                                                                                                                                
  \[[@B24-ijms-19-01487]\] Kim et al., 2013                                                                                                                                                 
  \[[@B37-ijms-19-01487]\] Harada et al., 2002b                                                                                                                                             
  \[[@B38-ijms-19-01487]\] Harada et al., 2004                                                                                                                                              
  \[[@B39-ijms-19-01487]\] Harada et al., 2006                                                                                                                                              
  \[[@B40-ijms-19-01487]\] Nameda et al., 2003                                                                                                                                              
  \[[@B41-ijms-19-01487]\] Yao et al., 2008                                                                                                                                                 
  \[[@B25-ijms-19-01487]\] Lee et al., 2016a                                                                                                                                                
  \[[@B26-ijms-19-01487]\] Park et al., 2016                                                                                                                                                
  \[[@B27-ijms-19-01487]\] Lee et al., 2016b                                                                                                                                                
  \[[@B45-ijms-19-01487]\] Lee et al., 2013b                                                                                                                                                
  Risk of bias rating                                                            Low risk of bias                               High risk of bias                                           Unclear
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###### 

Summary of standardized mean difference (SMD) comparison between control and *S. crispa* groups.

  -------------------------------------------------------------------------------------------------------------------------------------------
  Medical Application              No. of Studies   Healing Effect                *n*   SMD (95% CI)            I^2^   Total Effect
  -------------------------------- ---------------- ----------------------------- ----- ----------------------- ------ ----------------------
  Diabetes treatment               7                Serum glucose level (mg/dL)   33    3.52 (−0.16, 7.21)      94%    SMD = 1.29\
                                                                                                                       95% CI (0.47, 2.11)\
                                                                                                                       I^2^ = 91.9%

  Serum insulin level (mg/dL)      18               1.92 (1.10, 2.75)             0%                                   

  Nutrition intake (mL)            36               0.32 (−0.15, 0.78)            0%                                   

  Body weight (g)                  46               −0.60 (−1.61, 0.41)           78%                                  

  Wound closure rate (%)           40               3.55 (2.56, 4.54)             40%                                  

  Cancer treatment                 19               Tumor activity                67    2.22 (1.69, 2.75)       42%    

  Cancer cell survival (%)         58               23.05 (18.02, 28.08)          34%                                  

  IFN- γ production (ng/mL)        43               −0.34 (−0.37, −0.31)          99%                                  

  Anti-inflammatory activity       4                NO production (mg)            19    4.81 (3.30, 6.33)       50%    

  Inflammatory cell survival (%)   11               9.03 (0.80, 17.27)            47%                                  

  Anti-fungal activity             3                Anti-fungal activity          46    0.20 (−0.23, 0.62)      44%    

  Antioxidant activity             6                Anti-oxidant activity         14    −7.72 (−10.96, −4.49)   0%     

  DPPH (%)                         14               −26.50 (−38.35, −14.64)       10%                                  
  -------------------------------------------------------------------------------------------------------------------------------------------
